Overview

Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Status:
Completed

Trial end date:
2005-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine if TLK286(Telcyta) is more effective than gefitinib (Iressa) in the treatment of non-small cell lung cancer.

Phase:

Phase 3

Details

Lead Sponsor:

Telik

Treatments:

Gefitinib